Publications by authors named "P O Rumyantsev"
Clinical oncology is currently undergoing a period of unprecedented change. Targeted therapy, and subsequently immunotherapy, has revolutionized the clinical course and outcome of many patients with solid cancer. Clinical oncology is inseparable from molecular oncology, the development of which is interconnected.
View Article and Find Full Text PDFArticle Synopsis
- - Sorafenib and lenvatinib are multikinase inhibitors approved for treating patients with radioactive iodine-refractory differentiated thyroid cancer, and this study aimed to evaluate how long these patients remain asymptomatic after starting treatment.
- - The study included 647 patients, with a median observation period of 35.5 months, comparing two groups: those who started treatment with an MKI at the study's start and those who did not.
- - Results showed a median time to symptomatic progression of 55.4 months overall, with 64.5% of patients remaining asymptomatic for over 36 months, while 70% of patients on sorafenib experienced dose modifications and 89% had treatment-related side effects
Rationale: Insufficient world-wide clinical experience in radioiodine therapy (RIT) for Graves' disease (GD) in children and adolescents, and limited knowledge of the predictors of RIT efficacy.
Aims: Analysis and identification of the most significant predictors of the efficacy of RIT in children and adolescents with Graves' disease.
Materials And Methods: A total of 55 patients (48 females and 7 males) aged from 8 to 18 years receiving primary RIT for GD were enrolled.
[Hereditary cancer syndromes: a modern paradigm].
Probl Endokrinol (Mosk)
September 2020
About 5-10% of malignant neoplasms (MN) are hereditary. Carriers of mutations associated with hereditary tumor syndromes (HTS) are at high risk of developing tumors in childhood and young age and synchronous and metachronous multiple tumors. At the same time, this group of diseases remains mainly an oncological problem, and clinical decisions are made only when MNs are detected in carriers of pathogenic mutations.
View Article and Find Full Text PDF